Combination chemotherapy in advanced ovarian carcinoma

• Published in: Tumori Vol. 72; no. 5; p. 519
• Main Authors: Amadori, D, Ravaioli, A, Maltoni, M, Ridolfi, R, Gentilini, P, Giunchi, D C, Frassineti, L, Falcini, F, Amadori, M
• Format: Journal Article
• Language: English
• Published: United States 31.10.1986
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cisplatin - therapeutic use; Cyclophosphamide - therapeutic use; Doxorubicin - therapeutic use; Female; Humans; Middle Aged; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - surgery
• ISSN: 0300-8916
• DOI: 10.1177/030089168607200513

Ovarian carcinoma is the fifth most common cause of death among women in western countries. It is often diagnosed in an advanced stage (FIGO Stage III and IV) and requires effective chemotherapy as first-line treatment. The advent of cis-platin combined with adriamycin and cyclophosphamide has remarkably increased the response rate in advanced disease. The authors report 31 cases of epithelial ovarian neoplasia, without prior chemotherapy, treated with cis-platin, adriamycin and cyclophosphamide (PAC I). Of the 30 evaluable patients, 15 had clinical complete remissions (cCR = 50%), 10 clinical partial remissions (cPR = 33%) and 5 no response (NR = 17%). The total response (cCR + cPR) was equal to 83%. Twelve of the 15 patients in cCR underwent second-look laparotomy; in 8 of these cases, histologic and cytologic confirmation of CR was obtained. PAC I was found to be a highly effective therapeutic regimen with moderate toxicity. The individual toxicity reported was gastroenteric (nausea and vomiting), but transitory. No chronic toxic side-effects from cisplatin or adriamycin were noted. However, more definitive results must be obtained to verify its impact on the prolongation of survival.